Edition:
India

Albireo Pharma Granted Orphan Designation By European Commission


Tuesday, 18 Dec 2018 

Dec 18 (Reuters) - Albireo Pharma Inc ::ALBIREO GRANTED ORPHAN DESIGNATION BY EUROPEAN COMMISSION FOR LEAD PRODUCT CANDIDATE A4250 FOR TREATMENT OF BILIARY ATRESIA.ALBIREO PHARMA - PLAN TO EXPAND DEVELOPMENT OF A4250 IN RARE CHOLESTATIC LIVER DISEASES IN 2019.ALBIREO PHARMA - ORPHAN DESIGNATION PROVIDES 10 YEARS MARKET EXCLUSIVITY UPON APPROVAL PLUS 2 YEARS UPON COMPLETION OF PEDIATRIC INVESTIGATION PLAN. 

Company Quote

20.24
-0.76 -3.62%
13 Dec 2019